Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026)

Cytosorbents' Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $300000.0 for Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340000.0 (up 296.46% YoY) and the FY2025 annual result came in at $40000.0, down 65.22% from the prior year.
• Asset Writedowns and Impairment was $300000.0 for Q1 2026 at Cytosorbents, up from $23000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $462237.0 in Q3 2023 and bottomed at -$461187.0 in Q4 2023.
• A 5-year average of $69065.0 and a median of $20209.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 6533.08% — and 2023, when it sank 661.72%.
• Cytosorbents' Asset Writedowns and Impairment stood at $204180.0 in 2022, then sank by 325.87% to -$461187.0 in 2023, then surged by 101.73% to $8000.0 in 2024, then soared by 187.5% to $23000.0 in 2025, then soared by 1204.35% to $300000.0 in 2026.
• Business Quant data shows CTSO's Asset Writedowns and Impairment at $300000.0 in Q1 2026, $23000.0 in Q4 2025, and $8000.0 in Q3 2025.